NCT03069651

Virtual Care in CF (VIRTUAL-CF) Study

Status unknown NA Last updated 11 February 2020

What this trial tests

NA trial testing Virtual Care in Cystic Fibrosis in 100 participants. Status unknown.

Timeline

29 March 2016

Primary endpoint
31 December 2017

31 December 2020

Quick facts

Lead sponsor	Heart of England NHS Trust
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	100
Start date	29 March 2016
Primary completion	31 December 2017
Estimated completion	31 December 2020
Sites	1 location across United Kingdom

Drugs / interventions tested

• Virtual Care

Conditions studied

• Cystic Fibrosis — all drugs for Cystic Fibrosis →

Sponsor

Heart of England NHS Trust

Who can join

18 and older, any sex, with Cystic Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cystic fibrosis (CF) is the most common fatal inherited condition in Caucasians, causing recurrent chest infections (pulmonary exacerbations). People with CF experiencing pulmonary exacerbation often require a 14day course of intravenous antibiotics and this treatment can either be delivered in hospital or in the community. Patients admitted to hospital are seen regularly by members of the CF multidisciplinary team (MDT), including doctors, nurses, dieticians and physiotherapists. This allows patients' progress to be closely monitored and also gives patients the opportunity to discuss any concerns or questions. In contrast, patients receiving IV antibiotics in the community are only seen by the MDT at the beginning and end of their 14 day course of IV antibiotics. Although CF nurses often visit patients on 12 occasions during the course of treatment, patients are not routinely reassessed by the rest of the MDT. There is therefore less opportunity for the MDT to adjust patients' treatment and for patients to communicate with the MDT.

We therefore aim to study whether patients receiving IV antibiotics in the community benefit from monitoring their own oxygen saturations and lung function, as well as taking part in twice-weekly videoconferences with the MDT ('virtual care'). We expect that this will enable the MDT to to assess patients' progress more closely and allow patients to communicate with the MDT more easily. We will assess whether this improves patients' experience of their care and whether this translates into improvements in health and economic outcomes.

One hundred subjects will be recruited over a 12month period, with 50 subjects allocated to 'virtual care' and 50 subjects allocated to 'routine care'. Subjects receiving 'routine care' will receive usual clinical care.

The research team are well placed to perform the study because we are part of a large CF centre with an excellent record in clinical research.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.